Abstract
Fenfluramine is an antiseizure medication for the treatment of Dravet and Lennox–Gastaut syndromes. This review summarizes the literature on the efficacy and tolerability of fenfluramine and presents recommendations for practical therapeutic management. With regular monitoring, this medication is generally well tolerated and to date has shown no cardiac side effects such as valve insufficiency or pulmonary hypertension in the clinical development program. However, children may experience a loss of appetite and should be closely monitored for weight loss, and sedation was observed in several overweight patients due to rapid dosage titration; therefore, a slower dosage increase than recommended might be needed for children and adults. Drug interactions should be considered before and during therapy, and dosage reductions are necessary when the medication is used in combination with stiripentol. Furthermore, bromide levels could increase with this medication. Contact with the patient or their relatives is important to determine the general state of health, potential movement disturbances, and seizure frequency so as to allow for timely dosage adjustments during the titration phase.
Introduction
Fenfluramine (FFA) has undergone a significant clinical re-emergence as a potent treatment for rare, treatment-resistant epilepsies. Originally used as a high-dose appetite suppressant in the 1990s, FFA was withdrawn due to concerns regarding cardiac valvulopathy. However, modern research has repurposed the drug at significantly lower doses (maximum 26 mg/day) to provide life-changing seizure reduction for patients with Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS). These developmental and epileptic encephalopathies are notoriously resistant to standard medications and carry a high risk of cognitive decline and Sudden Unexpected Death in Epilepsy (SUDEP).
Mechanism of Action
The efficacy of fenfluramine stems from a mechanism of action that is distinct from most traditional antiseizure medications (ASMs). It primarily functions through two pathways:
- Serotonergic Modulation: FFA increases synaptic serotonin levels and acts directly on specific 5-HT receptors, notably 5-HT1D and 5-HT2C. This modulation occurs across various brain regions, including the raphe nuclei and thalamus.
- Sigma-1 Receptor Targeting: FFA acts as a ligand for the sigma-1 receptor, a chaperone protein that modulates voltage-gated ion channels and neurotransmitter receptors, providing a synergistic effect with other ASMs.
Clinical Efficacy and Key Results
The clinical utility of FFA is supported by a robust body of evidence from Phase III double-blind, placebo-controlled trials and real-world Compassionate Use Programs (CUPs).
- Dravet Syndrome (DS): Phase III trials demonstrated a 54–68% responder rate (patients achieving ≥50% reduction in convulsive seizures), compared to just 5–12% in placebo groups. Long-term follow-up data indicates sustained efficacy, with some patients achieving complete seizure freedom.
- Lennox–Gastaut Syndrome (LGS): FFA significantly reduced "drop seizures," with a median reduction of 26.5% at the 0.7 mg/kg/day dose.
Safety and Practical Management
A primary concern for clinicians is cardiac safety. To date, no cases of valvular heart disease or pulmonary hypertension have been observed in the epilepsy clinical development program, likely due to the lower dosing compared to historical weight-loss applications. Nevertheless, echocardiograms remain mandatory every 6–12 months as a precautionary measure.
Common side effects include decreased appetite, weight loss, and fatigue. Sedation has been noted particularly in overweight patients during rapid titration, suggesting that a slower up-dosing schedule may be beneficial.
Drug Interactions
Pharmacokinetic interactions are a critical consideration. Specifically, stiripentol inhibits the enzymes that metabolize FFA, necessitating a dose reduction (maximum 17 mg/day) when used in combination. Clinicians must also be mindful of other drugs that influence the serotonergic system to avoid the risk of serotonin syndrome.
Conclusion
Fenfluramine represents a significant advancement in the treatment of DS and LGS. By targeting non-standard pathways like the sigma-1 receptor and serotonergic system, it offers a powerful alternative for patients who have failed traditional therapies. While careful monitoring and individualized titration are required, the potential for profound seizure reduction makes FFA a vital tool in modern pediatric and adult neurology.
Summary updated